The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

NCT06975865 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

192

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Rilzabrutinib
DRUG: Placebo

Sponsor

Sanofi